GTPBP1 and chronic kidney disease: In vivo administration of GP1 had no impact on functional parameters, such as plasma levels of urea or creatinine (neither one nor two months after CKD induction) (Table 1), indicating that GP1 did not blunt renal dysfunction associated with CKD in the 5/6 nephrectomy model.